Payment overview · 2025
General Payments
$1,580.48
83 reported records · 20 companies
Healthcare provider profile · identity verified
Mark Lassiter Daniel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ELBERTON, GA · NPI 1700883659
Verified facts
What the public records show
CMS Open Payments records show Mark Lassiter Daniel, M.D. received $1,580.48 in general payments during 2025 across 83 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 14.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 274 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 583 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $227.22 | 14.4% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $180.12 | 11.4% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $144.09 | 9.1% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $114.14 | 7.2% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $105.44 | 6.7% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $102.70 | 6.5% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $98.85 | 6.2% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.82 | 6.1% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $83.60 | 5.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.61 | 4.2% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $62.12 | 3.9% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $60.74 | 3.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.38 | 3.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.53 | 3.0% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $32.12 | 2.0% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.86 | 1.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.36 | 1.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.74 | 1.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.71 | 1.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.33 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,580.48 | 83 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $246.96 | 11 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $180.12 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $144.09 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $114.14 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $102.70 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $75.10 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.46 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.61 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.61 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $62.12 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $60.74 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $54.07 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.37 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $43.25 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $42.85 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.75 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.39 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.17 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $32.12 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 583 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 274 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 112 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 135 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
274 | 43 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
62 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
84 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
112 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
135 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
583 | 39 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Famotidine | Famotidine | 1491 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 1273 | 184 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1263 | 233 |
| Furosemide | Furosemide | 1211 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1162 | 140 |
| Gabapentin | Gabapentin | 1123 | 133 |
| Potassium Chloride | Potassium Chloride | 1086 | 111 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 975 | 156 |
| Alprazolam | Alprazolam | 762 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 675 | 45 |
| Eliquis | Apixaban | 583 | 39 |
| Omeprazole | Omeprazole | 538 | 81 |
| Mirtazapine | Mirtazapine | 533 | 33 |
| Lisinopril | Lisinopril | 530 | 87 |
| Donepezil Hcl | Donepezil Hcl | 493 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 477 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 474 | 35 |
| Memantine Hcl | Memantine Hcl | 461 | 25 |
| Trazodone Hcl | Trazodone Hcl | 460 | 37 |
| Tramadol Hcl | Tramadol Hcl | 452 | 94 |
| Metoprolol Tartrate | Metoprolol Tartrate | 447 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 438 | 56 |
| Prednisone | Prednisone | 425 | 230 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 397 | 103 |
| Divalproex Sodium | Divalproex Sodium | 384 | 19 |
| Metformin Hcl | Metformin Hcl | 351 | 69 |
| Cefuroxime | Cefuroxime Axetil | 346 | 234 |
| Carvedilol | Carvedilol | 344 | 47 |
| Valsartan | Valsartan | 340 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 319 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 309 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 306 | 20 |
| Risperidone | Risperidone | 301 | 22 |
| Clonazepam | Clonazepam | 295 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 295 | 63 |
| Allopurinol | Allopurinol | 289 | 42 |
| Losartan Potassium | Losartan Potassium | 278 | 59 |
| Farxiga | Dapagliflozin Propanediol | 274 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 274 | 33 |
| Lorazepam | Lorazepam | 271 | 42 |
| Sertraline Hcl | Sertraline Hcl | 266 | 33 |
| Xarelto | Rivaroxaban | 265 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 264 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 261 | 27 |
| Buspirone Hcl | Buspirone Hcl | 259 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 255 | 49 |
| Quetiapine Fumarate | Quetiapine Fumarate | 250 | 21 |
| Labetalol Hcl | Labetalol Hcl | 242 | 38 |
| Oxycodone Hcl | Oxycodone Hcl | 239 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 238 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 233 | 168 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 231 | 19 |
| Meloxicam | Meloxicam | 227 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 218 | 70 |
| Glipizide | Glipizide | 214 | 31 |
| Probenecid-Colchicine | Probenecid/Colchicine | 201 | 32 |
| Nebivolol Hcl | Nebivolol Hcl | 197 | 33 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 194 | 14 |
| Atenolol | Atenolol | 189 | 19 |
| Simvastatin | Simvastatin | 187 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 180 | 49 |
| Glipizide Er | Glipizide | 173 | 43 |
| Baclofen | Baclofen | 170 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 168 | 39 |
| Ondansetron Hcl | Ondansetron Hcl | 168 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 164 | 16 |
| Levetiracetam | Levetiracetam | 164 | 14 |
| Promethazine Hcl | Promethazine Hcl | 163 | 58 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 161 | 48 |
| Glyxambi | Empagliflozin/Linagliptin | 152 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 152 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 147 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 143 | 36 |
| Torsemide | Torsemide | 142 | 12 |
| Bupropion Xl | Bupropion Hcl | 141 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 139 | 28 |
| Ondansetron Odt | Ondansetron | 138 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 137 | 22 |
| Mounjaro | Tirzepatide | 135 | 17 |
| Fluconazole | Fluconazole | 132 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 30 |
| Lamotrigine | Lamotrigine | 131 | suppressed |
| Diazepam | Diazepam | 130 | 14 |
| Olanzapine | Olanzapine | 130 | suppressed |
| Digoxin | Digoxin | 129 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 128 | 32 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 127 | 77 |
| Ezetimibe | Ezetimibe | 127 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 126 | 11 |
| Clonidine Hcl | Clonidine Hcl | 122 | 17 |
| Montelukast Sodium | Montelukast Sodium | 119 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 119 | 38 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 117 | 18 |
| Jardiance | Empagliflozin | 112 | 16 |
| Pregabalin | Pregabalin | 112 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 107 | suppressed |
| Celecoxib | Celecoxib | 106 | 25 |
| Ibuprofen | Ibuprofen | 103 | 21 |
| Sucralfate | Sucralfate | 100 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 98 | 21 |
| Ozempic | Semaglutide | 93 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 87 | 61 |
| Methenamine Hippurate | Methenamine Hippurate | 87 | suppressed |
| Indomethacin | Indomethacin | 85 | 34 |
| Meclizine Hcl | Meclizine Hcl | 85 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 14 |
| Alendronate Sodium | Alendronate Sodium | 82 | 15 |
| Spironolactone | Spironolactone | 80 | suppressed |
| Irbesartan | Irbesartan | 79 | 13 |
| Midodrine Hcl | Midodrine Hcl | 77 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 76 | 21 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 76 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 76 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 73 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 70 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 69 | suppressed |
| Estradiol | Estradiol | 68 | 11 |
| Nifedipine Er | Nifedipine | 68 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 67 | 15 |
| Roflumilast | Roflumilast | 67 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 66 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 65 | 15 |
| Mupirocin | Mupirocin | 62 | 39 |
| Symbicort | Budesonide/Formoterol Fumarate | 62 | 20 |
| Verapamil Er | Verapamil Hcl | 60 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 59 | suppressed |
| Topiramate | Topiramate | 57 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 56 | 14 |
| Terazosin Hcl | Terazosin Hcl | 56 | suppressed |
| Carisoprodol | Carisoprodol | 55 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 54 | 33 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 53 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 53 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 52 | 23 |
| Linzess | Linaclotide | 52 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 51 | suppressed |
| Creon | Lipase/Protease/Amylase | 50 | suppressed |
| Nystatin | Nystatin | 50 | 25 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 49 | 43 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Lovastatin | Lovastatin | 48 | 11 |
| Memantine Hcl Er | Memantine Hcl | 48 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 48 | suppressed |
| Glimepiride | Glimepiride | 47 | 14 |
| Metolazone | Metolazone | 47 | 15 |
| Phenobarbital | Phenobarbital | 47 | suppressed |
| Ketoconazole | Ketoconazole | 46 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | 11 |
| Bethanechol Chloride | Bethanechol Chloride | 45 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 44 | suppressed |
| Phenelzine Sulfate | Phenelzine Sulfate | 44 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 13 |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Azithromycin | Azithromycin | 43 | 36 |
| Cephalexin | Cephalexin | 42 | 23 |
| Finasteride | Finasteride | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 39 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Klor-Con M20 | Potassium Chloride | 37 | 11 |
| Levemir Flexpen | Insulin Detemir | 37 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | 15 |
| Lubiprostone | Lubiprostone | 35 | 11 |
| Temazepam | Temazepam | 35 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Perphenazine | Perphenazine | 33 | suppressed |
| Rybelsus | Semaglutide | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 12 |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 32 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 32 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 19 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | 12 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 29 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 29 | suppressed |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 29 | 28 |
| Sps | Sodium Polystyrene Sulfon/Sorb | 29 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 29 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 28 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Permethrin | Permethrin | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 24 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 17 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 25 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 12 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Methadone Hcl | Methadone Hcl | 15 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 14 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 12 |
| Nortrel | Norethindrone-Ethin. Estradiol | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Terconazole | Terconazole | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Clarithromycin | Clarithromycin | 12 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Ethacrynic Acid | Ethacrynic Acid | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,580.48 · 83 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error